Heyholder
‹ Activism Filings

Cellromax Science Co., Ltd. Q3 operating profit KRW 0.8 billion, up 12.1% from a year earlier

Cellromax Science Co., Ltd.· Periodic Report

AI summary · Not investment advice

Celomax Science sold KRW 4.9 billion in Q3 and earned KRW 0.8 billion from its main business, up 12.1% from a year earlier and down 15.8% from the prior quarter.

Operating profit · 3 months

KRW 825.9 million

Key facts

Revenue (3 months)
KRW 4.9 billion
Net income (3 months)
KRW 807.4 million
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 5.3 billion
Revenue (year to date)
KRW 14.7 billion
Operating profit (prior-year 3 months)
KRW 736.7 million
Operating profit (year to date)
KRW 2.2 billion
Net income (prior-year 3 months)
KRW 757.4 million
Net income (year to date)
KRW 2.8 billion

Commentary

AI commentary · Not investment advice

What happened

Cellomax Science reported its consolidated results for the 3rd quarter of 2026. Sales for the 3 months were KRW 4.93 billion. That is 7.5% lower than the same period a year earlier and 3.0% lower than the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was KRW 826 million. That is 12.1% higher than a year earlier and 15.8% lower than the previous quarter. Net income (the final profit after taxes and other costs) for the 3 months was KRW 807 million. That is 6.6% higher than a year earlier.

What changes for shareholders

For the year to date (Jan 1 to Sep 30), sales were KRW 14.73 billion. Operating profit was KRW 2.16 billion. Net income was KRW 2.80 billion.

Comments

No comments yet

Comments from shareholders will appear here.